Skip to content
DraconiticResearch
Search Sources API
189,280 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NC-NDClinical parkinsonism & related disorders

Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale.

  • Anna-Karin Berger1
  • Andreas Rieckmann1
  • Krishan Nighah1
  • Stefano Zanigni1
  1. 1H. Lundbeck A/S, DK-2500 Valby, Copenhagen, Denmark.
Read full textPDFDOICite

Abstract

Background

Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.Objectives

To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).Methods

Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.Results

For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from r = 0.51-0.72, comparable to the UMSARS Total score (r = 0.49-0.69) and higher than UMSARS Part I (r = 0.42-0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64-2.92) and lower in no-change groups (0.97-1.62).Conclusions

The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.

Related

  1. Resting-state cortical alpha frequency in Parkinson’s disease and multiple system atrophy: associations with diagnosis, age, and symptom burden
    Daichao Chen, Huada Tang, Yanfei Pan +11
    Frontiers in aging neurosciencePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Acute Respiratory Failure Associated with Severe Obstructive Sleep Apnea as an Early Manifestation of Multiple System Atrophy: A Case Report
    Yuki Hagiwara, Takamichi Kanbayashi, Shunsuke Kobayashi
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textPhysiologyJ-STAGE
  3. Defining the clinical benefits of disease-modifying therapy in people living with spinal muscular atrophy who require permanent ventilation: a UK-based modified Delphi consensus process
    Mariacristina Scoto, Chiara Marini-Bettolo, Elaine Chan +17
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0Full textHuman geneticsCrossrefDOAJEurope PMCPMC
  4. Characterizing progressive cortical thinning in multiple system atrophy: a longitudinal MRI study
    Riccardo Iandolo, Marco Aiello, Francesco Tommasino +10
    npj Parkinson's DiseasePeer-reviewedCC BYFull textNeurologyDOAJ
  5. Thalamic atrophy in active and inactive secondary progressive multiple sclerosis patients: A comparative study
    Shadi Bahrami, Neda Ramezani, Mohammad Yazdan Panah +6
    Caspian Journal of Internal MedicinePeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{berger2026psychometric,
  title = {{Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale.}},
  author = {Anna-Karin Berger and Andreas Rieckmann and Krishan Nighah and Stefano Zanigni},
  journal = {Clinical parkinsonism \& related disorders},
  year = {2026},
  month = oct,
  doi = {10.1016/j.prdoa.2026.100510},
  url = {https://europepmc.org/article/MED/42927221},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale.
AU  - Anna-Karin Berger
AU  - Andreas Rieckmann
AU  - Krishan Nighah
AU  - Stefano Zanigni
PY  - 2026
DA  - 2026/10/13
JO  - Clinical parkinsonism & related disorders
DO  - 10.1016/j.prdoa.2026.100510
UR  - https://europepmc.org/article/MED/42927221
AB  - Background  Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.Objectives  To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).Methods  Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.Results  For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from r = 0.51-0.72, comparable to the UMSARS Total score (r = 0.49-0.69) and higher than UMSARS Part I (r = 0.42-0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64-2.92) and lower in no-change groups (0.97-1.62).Conclusions  The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.
SN  - 2590-1125
ER  -